Amylyx Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Amylyx Pharmaceuticals

07/11/2024 17:20

* Amylyx Pharmaceuticals Inc  AMLX.OQ  reported a quarterly
adjusted loss of $1.07​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of 30 cents.  The mean expectation of
five analysts for the quarter was for a loss of 71 cents per
share. Wall Street expected results to range from $-1.26 to -42
cents per share.
    * Revenue fell 99.6% to $416.00 thousand from a year ago;
analysts
expected zero. 
    * Amylyx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.07​.
    * The company reported a quarterly loss of $72.7 million.
    * Amylyx Pharmaceuticals Inc shares had risen by 92.0% this
quarter and lost 57.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Amylyx
Pharmaceuticals Inc is 4.00 
This summary was machine generated from LSEG data November 7 at
05:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.71          -1.07          Missed
 Jun. 30 2024      -0.73          -0.73          Met
 Mar. 31 2024      -0.01          -0.12          Missed
 Dec. 31 2023      0.23           0.07           Missed